Aeglea BioTherapeutics

Aeglea BioTherapeutics is a late clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. We partnered with 22 Fillmore, a brand consultancy in the Bay Area, to deliver a full corporate rebrand that included a new positioning platform, identity system, campaign development and an overhaul of the company website.